This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trovagene Launches Easier Test For HPV Infection

There are at least a few dozen types of HPV. Different types can cause cancer of the cervix, genital warts, warts growing in the throat and, less commonly, cancers of the throat, vagina, vulva, penis and anus.

About 90 percent of HPV infections go away on their own within a couple of years, knocked out by the body's immune system. Patients diagnosed with an HPV infection typically get follow-up tests every six to 12 months to see whether the infection has cleared up or persisted long enough to require treatment.

The Trovagene test, soon to be available through health care providers, would make follow-up tests after diagnosis easier.

Chances of HPV infection can be reduced by use of condoms, limiting number of sexual partners and immunization against most disease-causing types. Two vaccines are recommended for adolescent boys and girls and for men and women through age 26: Merck & Co.'s Gardasil and GlaxoSmithKline PLC's Cervarix.

Trovagene shares rose 35 cents, or 6.1 percent, to $6.10 in regular trading Wednesday, then climbed another 65 cents, or 10.7 percent, to $6.75 in after-hours trading. Shares have traded in a range of $1.86 to $8.96 over the past 52 weeks.

___

Follow Linda A. Johnson on Twitter at http://twitter.com/LindaJ_onPharma

Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs